Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Seagen Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1998-01-01

Employees: 3.2K

Market Cap: -

Website: http://www.seagen.com

Clinical Trials

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Acute Myelogenous Leukemia

Interventions: Drug: Standard dose cytarabine for induction
Drug: High dose cytarabine for consolidation
Drug: SGN-CD33A
Drug: Daunorubicin

First Posted Date: 2014-12-29

Last Posted Date: 2018-05-09

Lead Sponsor: Seagen Inc.

Target Recruit Count: 116

Registration Number: NCT02326584

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

and more 10 locations

Safety Study of SGN-CD70A in Cancer Patients

Phase 1

Completed

Conditions: Diffuse, Large B-Cell, Lymphoma
Follicular Lymphoma, Grade 3
Mantle-Cell Lymphoma
Renal Cell Carcinoma

Interventions: Drug: SGN-CD70A

First Posted Date: 2014-08-15

Last Posted Date: 2018-04-19

Lead Sponsor: Seagen Inc.

Target Recruit Count: 38

Registration Number: NCT02216890

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States

and more 14 locations

A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

Phase 1

Completed

Conditions: HER2 Positive Metastatic Breast Cancers

Interventions: Drug: Tucatinib
Drug: Capecitabine
Drug: Trastuzumab

First Posted Date: 2013-12-31

Last Posted Date: 2020-06-04

Lead Sponsor: Seagen Inc.

Target Recruit Count: 60

Registration Number: NCT02025192

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Providence Cancer Center, Portland, Oregon, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 2 locations

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Phase 1

Completed

Conditions: Esophagus Cancer
Ovary Cancer
Prostate Cancer (CRPC)
Lung Cancer(NSCLC)
Cervix Cancer
Endometrium Cancer
Bladder Cancer
Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Interventions: Drug: Tisotumab Vedotin (HuMax-TF-ADC)

First Posted Date: 2013-12-05

Last Posted Date: 2021-12-29

Lead Sponsor: Seagen Inc.

Target Recruit Count: 195

Registration Number: NCT02001623

Locations: 🇺🇸
University of California Irvine Medical Center (UCIMC), Orange, California, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
University of Miami, Miami, Florida, United States

and more 26 locations

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

Phase 1

Completed

Conditions: HER2 Positive Breast Cancers

Interventions: Drug: Tucatinib (ONT-380)
Drug: T-DM1

First Posted Date: 2013-11-14

Last Posted Date: 2020-09-21

Lead Sponsor: Seagen Inc.

Target Recruit Count: 57

Registration Number: NCT01983501

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
University of Kansas, Kansas City, Kansas, United States

and more 8 locations

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Phase 1

Completed

Conditions: HER2 Positive Breast Neoplasms
Hormone Receptor Positive Breast Neoplasms
Triple Negative Breast Neoplasms
HER2 Mutations Breast Neoplasms

Interventions: Drug: ladiratuzumab vedotin
Drug: Trastuzumab

First Posted Date: 2013-10-25

Last Posted Date: 2023-03-07

Lead Sponsor: Seagen Inc.

Target Recruit Count: 290

Registration Number: NCT01969643

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Pinnacle Oncology Hematology, Scottsdale, Arizona, United States
🇺🇸
UC San Diego / Moores Cancer Center, La Jolla, California, United States

and more 35 locations

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2

Terminated

Conditions: Lymphoma, B-cell
Lymphoma, Large B-cell, Diffuse

Interventions: Drug: brentuximab vedotin
Drug: rituximab
Drug: cyclophosphamide
Drug: vincristine
Drug: prednisone
Drug: doxorubicin

First Posted Date: 2013-08-20

Last Posted Date: 2018-06-21

Lead Sponsor: Seagen Inc.

Target Recruit Count: 87

Registration Number: NCT01925612

Locations: 🇺🇸
Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States
🇺🇸
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 48 locations

A Safety Study of SGN-CD33A in AML Patients

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Acute Promyelocytic Leukemia

Interventions: Drug: HMA
Drug: SGN-CD33A

First Posted Date: 2013-07-18

Last Posted Date: 2018-01-05

Lead Sponsor: Seagen Inc.

Target Recruit Count: 195

Registration Number: NCT01902329

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

and more 11 locations

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Phase 1

Completed

Conditions: Hodgkin Disease

Interventions: Drug: brentuximab vedotin
Drug: bendamustine

First Posted Date: 2013-06-10

Last Posted Date: 2019-02-12

Lead Sponsor: Seagen Inc.

Target Recruit Count: 55

Registration Number: NCT01874054

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Pacific Hematology Oncology Associates, San Francisco, California, United States
🇺🇸
Stanford Cancer Center, Stanford, California, United States

and more 10 locations

A Safety Study of SGN-CD19A for Leukemia and Lymphoma

Phase 1

Completed

Conditions: Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Burkitt Lymphoma

Interventions: Drug: SGN-CD19A

First Posted Date: 2013-02-07

Last Posted Date: 2017-07-02

Lead Sponsor: Seagen Inc.

Target Recruit Count: 92

Registration Number: NCT01786096

Locations: 🇺🇸
Children's Hospital of Alabama / University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy